Skip to main content

Table 2 Factors associated with low BMD and fracture at univariate analysis

From: Bone fragility in sarcoidosis and relationships with calcium metabolism disorders: a cross sectional study on 142 patients

  BMD < −1SD Fracture
  OR [95% CI] P OR [95% CI] P
Menopause 5.29 [1.83; 15.27] 0.002 2.1 [0.68; 6.53] 0.2
Age, years 1.06 [1.03; 1.1] <0.001 1.09 [1.05; 1.14] <0.001
Calcium intake <500 mg/d 4.28 [1.89; 9.72] <0.001 2.2 [0.93; 5.18] 0.072
Stage NHYA 3 or 4 3.34 [1.3; 8.54] 0.012 3.18 [1.23; 8.2] 0.017
Disease duration 1.05 [1; 1.1] 0.047 1 [0.95; 1.06] 0.9
Cumulative CS dose 1.15 [0.98; 1.36] 0.088 1.2 [0.99; 1.44] 0.059
Current CS treatment 1.68 [0.83; 3.4] 0.15 2.63 [1.08; 6.37] 0.033
Vitamin D supplements 3.82 [1.66; 8.8] 0.002 2.07 [0.87; 4.95] 0.1
BP treatment 3.03 [1.44; 6.36] 0.003 1.83 [0.8; 4.15] 0.15
ESR >10 mm/h 2.49 [1.1; 5.62] 0.028 1.38 [0.55; 3.46 0.5
Lymphocytes >1,000/mm3 0.45 [0.21; 0.94] 0.033 1.19 [0.5; 2.85] 0.7
Creatinine clearance, ml/mn 0.99 [0.98; 1] 0.034 0.97 [0.95; 0.99] <0.001
25(OH)D serum level     
25(OH)D ≤10 ng/ml 1 - 1 -
10 < 25(OH)D <20 ng/ml 0.48 [0.21; 1.09] 0.079 1.24 [0.45; 8.23] 0.67
25(OH)D >20 ng/ml 2.00 [0.8; 4.97] 0.13 2.94 [1.05; 8.23] 0.04
Serum PTH level, pmol/l     
Fracture/low BMD 4.39 [1.86; 10.37] <0.001 4.39 [1.86; 10.37] <0.001
  1. BMD, bone mineral density; BP, bisphosphonates; CS, Corticosteroids; ESR, erythrocyte sedimentation rate; PTH, parathyroid hormone; NYHA, New York Heart Association.